Signal active
Investment Firm
Overview
Blue Owl Capital is an alternative asset manager that provides investors access to direct lending and GP capital solutions strategies through a variety of vehicles. The firm's breadth of offerings and permanent capital base enables it to offer a differentiated, holistic platform of capital solutions to participants throughout the private market ecosystem, including alternative asset managers and private middle market corporations.
Highlights
2021
Financial Services
501-1000
28
9
11
Late Stage Venture, Early Stage Venture
Private Equity Firm
Location
New York, New York, United States, North America
Contact Information
Social
Profile Resume
Blue Owl, established in 2021 and headquartered in New York, New York, United States, North America., specializes in Late Stage Venture, Early Stage Venture investments across Information Technology, Financial Services, FinTech, Big Data, SaaS, Technical Support, Human Resources, Payments, Cloud Infrastructure, Bookkeeping and Payroll. The organization boasts a portfolio of 24 investments, with an average round size of $574.0M and 11 successful exits. Their recent investments include CloudPay, Rho Capital Partners, HealthCare Royalty Partners, Autobahn Therapeutics, Canaan Partners. The highest investment round they participated in was $931.2B. Among their most notable exits are CloudPay and Rho Capital Partners. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
28
3
9
11
Investments
28
Annouced Date | Organization Name | Industry | Money Raised |
---|---|---|---|
Jul 16, 2024 | Cardurion Pharmaceuticals | Biotechnology | 260.0M |
Jul 24, 2024 | Autobahn Therapeutics | Biotechnology | 100.0M |
Aug 06, 2024 | - | - | 250.0M |
Aug 08, 2024 | CloudPay | Information Technology | 120.0M |
Exits
11
Funding Timeline
28
4
1
Funding Rounds
28
Blue Owl has raised 28 rounds. Their latest funding was raised on Aug 08, 2024 from a Venture Round - CloudPay round.
Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
---|---|---|---|---|
Jul 16, 2024 | Series B - Cardurion Pharmaceuticals | - | 260.0M | - |
Jul 24, 2024 | Series C - Autobahn Therapeutics | - | 100.0M | - |
Aug 06, 2024 | Post-IPO Debt - TG Therapeutics | - | 250.0M | - |
Aug 08, 2024 | Venture Round - CloudPay | - | 120.0M | - |
Investors
7
Blue Owl is funded by 7 investor(s). ICONIQ Capital and Koch Companies Defined Benefit Master Trust Kantor are the most recent investors.
Investor Name | Lead Investor | Funding Round | Money Raised |
---|---|---|---|
ICONIQ Capital | No | Post-IPO Equity - Blue Owl | 1500.0M |
- | No | Post-IPO Debt - Blue Owl | 400.0M |
- | No | Post-IPO Debt - Blue Owl | 750.0M |
- | No | Post-IPO Debt - Blue Owl | 250.0M |
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
Annouced Date | Fund Name | Money Raised |
---|---|---|
May 10, 2013 | OTPPLESS | 1.0M |
May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.